Creatine Study at Indiana University
Indiana University School of Medicine is one of 51 sites around the United States and Canada who are studying the effects of creatine on people with Parkinson’s disease. Creatine, a normal body chemical, is also a dietary supplement thought to improve muscle strength. However, it may also preserve nerve cells that die in Parkinson’s patients, which could slow the progression of the disease.
The National Institutes of Health (NIH) is recruiting 1,720 early-stage participants (5 years or less since diagnosis) for this major study. Participants must be treated/responsive to dopaminergic therapy (dopamine agonists or levodopa) for at least 90 days, but not more than 2 years. They will be evaluated over a minimum period of five years. The double-blind, placebo-controlled Phase III study is one of the largest Parkinson’s clinical trials.
For more information on the NET-PD LS-1 Creatine in Parkinson’s study, contact Joann Belden with Indiana University School of Medicine at 317-278-0868 or go to www.pdtrials.org